Strategic Delay: How CMR Surgical's Pause Set the Stage for Its U.S. Robotics Assault

This analysis is based on reporting originally published by MedTech Dive. Subscribe to their newsletter for daily medtech insights.

Editor’s Note: This piece is part of an ongoing series profiling innovators in surgical robotics.

CAMBRIDGE, England — For a new CEO, the temptation to launch a long-awaited product is powerful. For Massimiliano Colella of CMR Surgical, the greater power lay in saying "not yet."

Days after his appointment in late 2024, Colella faced a pivotal choice. The company's Versius soft tissue surgical robot had just secured its first FDA clearance and was poised for a U.S. rollout. Instead, Colella pulled the plug, delaying market entry by a full year to wait for a significantly upgraded platform, Versius Plus.

"It was my first major decision," Colella recalled in an exclusive interview. "Launching a 'Generation One' product into the most demanding surgical robotics market felt like a misstep. We needed to be certain."

That decision, while costly in time, may prove to be a masterstroke in timing. CMR Surgical now enters the U.S. market at a moment of unprecedented flux. For two decades, Intuitive Surgical's da Vinci system has dominated with minimal challenge. Today, a wave of competitors, including Medtronic and Johnson & Johnson, is finally arriving, promising to reshape the landscape and potentially lower costs.

CMR is no novice. Outside the U.S., Versius is the second-most widely adopted surgical robot, having performed over 40,000 procedures across 30+ countries since its 2019 CE mark. Backed by nearly $1.5 billion in venture capital—making it the top-funded VC-backed surgical device firm per PitchBook—the company has built substantial global experience.

The extra year allowed CMR to refine Versius into "Versius Plus," incorporating enhanced visualization, new instruments, data analytics tools, and improved system efficiency. Many upgrades are deployable via software to existing Versius systems. The robot's core differentiators remain: its modular, portable design replicates laparoscopic surgery and allows sharing between operating rooms—a direct contrast to Intuitive's larger, fixed systems.

"In massive hospitals, you can't have 20 dedicated robots," Colella explained. "A portable system that rotates between departments or ASCs [Ambulatory Surgery Centers] unlocks access for specialties previously sidelined."

The FDA cleared Versius Plus for gallbladder surgery in December. Clearances for gynecology, urology, gastrointestinal, and general surgery are anticipated this year, guiding a phased U.S. rollout. CMR is currently selecting initial hospital and ASC partners from what Colella calls a "healthy queue" of interested centers.

Despite the competitive rhetoric, Colella positions CMR as a complement, not a challenger. "We're not here to topple Intuitive," he stated. "The market is expanding globally, and there's space for differentiated products. Our arrival, alongside others, will accelerate overall market growth and improve accessibility for hospitals worldwide."

The strategic gamble is clear: trade a year's revenue for a stronger product entering a more receptive, competitive market. The surgical robotics race in the U.S. is no longer a solo sprint but a crowded marathon, and CMR believes its patience has given it the right shoes.

Industry Voices: Reactions to CMR's U.S. Entry

Dr. Anya Sharma, Chief of Robotic Surgery at a major Midwest hospital network: "The modularity is intriguing. Our ORs are booked solid. A system that can be wheeled from a general surgery procedure to a gynecology case later could dramatically improve our capital efficiency. We're evaluating them for exactly that niche."

Michael Trent, MedTech Analyst at Broadview Capital: "Colella's delay was a classic 'go-to-market' risk assessment. The U.S. is a graveyard for mediocre medtech. Launching an inferior product to beat competitors out the gate would have damaged their reputation irreparably. Their global traction proves the model works; now they must execute a flawless U.S. commercial launch."

Lisa Monroe, Patient Safety Advocate & Founder of "The Informed Scalpel": "Forgive me if I'm not cheering another multi-million dollar robot. Every new entrant claims it will lower costs, but we've seen the opposite for 20 years. More competition? Great. But until I see hard data on significantly lower procedure costs and improved patient outcomes across diverse populations, this is just more noise benefiting investors, not necessarily patients."

Prof. David Chen, Biomedical Engineering, Stanford: "The portability and software-upgradable architecture are the real innovations here. It's a more flexible, 'future-proof' approach to robotic surgery. If they can successfully navigate the FDA for additional indications, they could become a formidable #2 player by addressing the accessibility and cost concerns that have plagued the first generation of surgical robots."